{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:02:40Z","timestamp":1793394160417,"version":"4.5.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012023","name":"Stichting Sanquin Bloedvoorziening","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012023","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune hemolytic anemia (AIHA) is an acquired hemolytic disorder, mediated by auto-antibodies, and has a variable clinical course ranging from fully compensated low grade hemolysis to severe life-threatening cases. The rarity, heterogeneity and incomplete understanding of severe AIHA complicate the recognition and management of severe cases. In this review, we describe how severe AIHA can be defined and what is currently known of the severity and outcome of AIHA. There are no validated predictors for severe clinical course, but certain risk factors for poor outcomes (hospitalisation, transfusion need and mortality) can aid in recognizing severe cases. Some serological subtypes of AIHA (warm AIHA with complement positive DAT, mixed, atypical) are associated with lower hemoglobin levels, higher transfusion need and mortality. Currently, there is no evidence-based therapeutic approach for severe AIHA. We provide a general approach for the management of severe AIHA patients, incorporating monitoring, supportive measures and therapeutic options based on expert opinion. In cases where steroids fail, there is a lack of rapidly effective therapeutic options. In this era, numerous novel therapies are emerging for AIHA, including novel complement inhibitors, such as sutimlimab. Their potential in severe AIHA is discussed. Future research efforts are needed to gain a clearer picture of severe AIHA and develop prediction models for severe disease course. It is crucial to incorporate not only clinical characteristics but also biomarkers that are associated with pathophysiological differences and severity, to enhance the accuracy of prediction models and facilitate the selection of the optimal therapeutic approach. Future clinical trials should prioritize the inclusion of severe AIHA patients, particularly in the quest for rapidly acting novel agents.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1228142","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:57:35Z","timestamp":1695110255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps"],"prefix":"10.3389","volume":"14","author":[{"given":"Femke V. M.","family":"Mulder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masja","family":"de Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan J.","family":"Cruijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J.","family":"Bernelot Moens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2009.10.115","article-title":"Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies","volume":"28","author":"Klein","year":"2010","journal-title":"Vaccine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.26213","article-title":"Epidemiology of autoimmune hemolytic anemia: A nationwide population-based study in France","volume":"96","author":"Maquet","year":"2021","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2147\/CLEP.S250250","article-title":"Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980\u20132016","volume":"12","author":"Hansen","year":"2020","journal-title":"Clin Epidemiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10061244","article-title":"Epidemiology of secondary warm autoimmune haemolytic anaemia\u2014a systematic review and meta-analysis","volume":"10","author":"Tranek\u00e6r","year":"2021","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/TRF.16513","article-title":"Multiorgan failure in a fatal case of autoimmune hemolytic anemia","volume":"61","author":"Anandappa","year":"2021","journal-title":"Transfusion (Paris)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.24047","article-title":"Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias","volume":"90","author":"Fattizzo","year":"2015","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1309\/LM9OWRF64OGQODEA","article-title":"Fatal autoimmune hemolytic anemia due to immunoglobulin G autoantibody exacerbated by epstein-barr virus","volume":"46","author":"Fadeyi","year":"2015","journal-title":"Lab Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018984","article-title":"Fatal fulminant hemolysis-associated pulmonary embolism in mixed-type autoimmune hemolytic anemia","volume":"99","author":"Imataki","year":"2020","journal-title":"Medicine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 Patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13122","article-title":"Retrospective analysis of 30 severe autoimmune hemolytic anemia patients treated by whole blood exchange transfusion","volume":"55","author":"Li","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/J.MEDCLI.2019.06.024","article-title":"Autoimmune haemolytic anaemias: A retrospective study of 93 patients","volume":"154","author":"Guti\u00e9rrez Jomarr\u00f3n","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/S12288-020-01326-4","article-title":"Clinical profile and severity of hemolysis in adult patients of primary autoimmune hemolytic anemia and their response to steroid: A prospective cohort study from single institution","volume":"37","author":"Ray","year":"2021","journal-title":"Indian J Hematol Blood Transfusion"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0959-3","article-title":"Characterization of red cell autoantibodies in consecutive DAT-positive patients with relation to in vivo haemolysis","volume":"84","author":"Wikman","year":"2005","journal-title":"Ann Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/S00277-008-0674-6","article-title":"Clinical and serological characterization of autoimmune hemolytic anemia in a tertiary care hospital in North India","volume":"88","author":"Das","year":"2009","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1764006","article-title":"Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States","volume":"23","author":"Su","year":"2020","journal-title":"J Med Econ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1960494","article-title":"Healthcare resource utilization among patients with cold agglutinin disease in Denmark","volume":"37","author":"V\u00e1g\u00f3","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3553-9","article-title":"Prognosis of autoimmune hemolytic anemia in critically ill patients","volume":"98","author":"Lafarge","year":"2019","journal-title":"Ann Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.26665","article-title":"Characteristics and outcome of adults with severe autoimmune hemolytic anemia admitted to the intensive care unit: Results from a large French observational study","volume":"97","author":"Pouchelon","year":"2022","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207218","article-title":"Venous thromboembolic events during warm autoimmune hemolytic anemia","volume":"13","author":"Audia","year":"2018","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5045\/br.2019.54.2.131","article-title":"Treatment of autoimmune hemolytic anemia: Real world data from a reference center in Mexico","volume":"54","author":"Jaime-P\u00e9rez","year":"2019","journal-title":"Blood Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X12473408860262","article-title":"Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia","volume":"14","author":"Nakasone","year":"2013","journal-title":"Hematology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2016.1138621","article-title":"Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia","volume":"21","author":"Rattarittamrong","year":"2016","journal-title":"Hematology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh303w","article-title":"Warm autoimmune hemolytic anemia: clinical profile and management","volume":"6","author":"Sudulagunta","year":"2017","journal-title":"Original Article J Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01103-y","article-title":"Clinical features and treatment outcomes of warm autoimmune hemolytic anemia: A retrospective analysis of 60 turkish patients","volume":"35","author":"Y\u0131lmaz","year":"2019","journal-title":". Indian J Hematol Blood Transfusion"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/EJH.13764","article-title":"Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up","volume":"109","author":"Hansen","year":"2022","journal-title":"Eur J Haematol"},{"key":"B33","article-title":"Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia","volume":"7","author":"Sallah","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10081764","article-title":"Thrombotic complications in patients with immune-mediated hemolysis","volume":"10","author":"Capecchi","year":"2021","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10062","article-title":"Autoimmune hemolytic anemia","volume":"69","author":"Gehrs","year":"2002","journal-title":"Am J Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/J.1537-2995.2008.01957.X","article-title":"Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies","volume":"49","author":"Arndt","year":"2009","journal-title":"Transfusion (Paris)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/J.1537-2995.2009.02533.X","article-title":"A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies","volume":"50","author":"Bartolm\u00e4s","year":"2010","journal-title":"Transfusion (Paris)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.18011","article-title":"A single dose of eculizumab terminated life-threatening haemolysis in idiopathic IgM-mediated warm autoimmune haemolytic anaemia: A case report","volume":"197","author":"Garg","year":"2022","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.02846.x","article-title":"Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old wOman","volume":"70","author":"Bardill","year":"2003","journal-title":"J Haematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37297203520.x","article-title":"IgA red cell autoantibodies and autoimmune hemolysis","volume":"37","author":"Sokol","year":"1997","journal-title":"Transfusion (Paris)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21307\/IMMUNOHEMATOLOGY-2022-047","article-title":"Clinical perspectives, immunohematologic insights, and transfusion management in IgA-associated autoimmune hemolytic anemia","volume":"38","author":"Das","year":"2022","journal-title":"Immunohematology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2022009402","article-title":"C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia","volume":"7","author":"De Boer","year":"2023","journal-title":"Blood Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019003808","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180509","article-title":"The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket","volume":"14","author":"Berentsen","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/BJH.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"B47","unstructured":"Richtlijn bloedtransfusiebeleid2011"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91056-R","article-title":"Transfusing patients with autoimmune haemolytic anaemia","volume":"341","author":"Garratty","year":"1993","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018739","article-title":"Autoimmune hemolytic anemia in hospitalized patients: 450 patients and their red blood cell transfusions","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2450\/2015.0326-14","article-title":"Precautions surrounding blood transfusion in autoimmune haemolytic anaemias are overestimated","volume":"13","author":"Y\u00fcrek","year":"2015","journal-title":"Blood Transfusion"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92766-9","article-title":"Red blood cell transfusion in warm-type autoimmune haemolytic anaemia","volume":"340","author":"Salama","year":"1992","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/hematology.2022000406","article-title":"Evaluating patients with auto immune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies","volume":"1","author":"Johnson","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/TRF.12639","article-title":"Immunosuppressants and alloimmunization against red blood cell transfusions","volume":"54","author":"Zalpuri","year":"2014","journal-title":"Transfusion (Paris)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014Evidence-based approach from the writing committee of the american society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3324\/HAEMATOL.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-167199","article-title":"Thrombotic and infectious complications in patients with autoimmune hemolytic anemia: A multicenter observational study","volume":"140","author":"Fattizzo","year":"2022","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/JTH.15757","article-title":"Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia","volume":"20","author":"Fattizzo","year":"2022","journal-title":"J Thromb Haemostasis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/J.BLRE.2021.100834","article-title":"It takes two to thrombosis: Hemolysis and complement","volume":"50","author":"Delvasto-Nu\u00f1ez","year":"2021","journal-title":"Blood Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/ejh.13710","article-title":"Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study","volume":"108","author":"Sch\u00e4r","year":"2022","journal-title":"Eur J Haematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.09.004","article-title":"Autoimmune hemolytic anemia and venous thromboembolism: A systematic review and meta-analysis","volume":"136","author":"Ungprasert","year":"2015"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10010164","article-title":"Infectious complications in autoimmune hemolytic anemia","volume":"10","author":"Giannotta","year":"2021","journal-title":"J Clin Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2018-99-119468","article-title":"Inhibition of C3 with APL-2 results in norMalisation of markers of intravascular and extravascular hemolysis in patients with autoimmune hemolytic anemia (AIHA)","volume":"132","author":"Grossi","year":"2018","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3324\/HAEMATOL.2021.279812","article-title":"Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results","volume":"107","author":"R\u00f6th","year":"2022","journal-title":"Haematologica"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2217\/IMT-2022-0085\/ASSET\/IMAGES\/LARGE\/FIGURE3.JPEG","article-title":"Sutimlimab for treatment of cold agglutinin disease: Why, how and for whom","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"},{"key":"B68","unstructured":"FDA approves treatment for adults with rare type of anemia2022"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/J.JACI.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V128.22.1265.1265","article-title":"ANX005, an inhibitory antibody against C1q, blocks complement activation triggered by cold agglutinins in human disease","volume":"128","author":"Gertz","year":"2016","journal-title":"Blood"},{"key":"B71","volume-title":"A safety and tolerability study of BIVV020 in adults with cold agglutinin Disease","year":"2020"},{"key":"B72","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.HS9.0000561876.96057.48","article-title":"S899 INHIBITION OF C3 WITH APL-2 CONTROLS HAEMOLYSIS AND INCREASES HAEMOGLOBIN LEVELS IN SUBJECTS WITH AUTOIMMUNE HAEMOLYTIC ANAEMIA (AIHA)","volume":"3","author":"Gertz","year":"2019","journal-title":"Hemasphere"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/pharmaceutics14051035","article-title":"Development of new drugs for autoimmune hemolytic anemia","volume":"14","author":"Xiao","year":"2022","journal-title":"Pharmaceutics"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844036.02998.15","article-title":"S286: Long-term efficacy and safety results from an ongoing open-label phase 2 study of parsaclisib for the treatment of autoimmune hemolytic anemia (aiha)","volume":"6","author":"Barcellini","year":"2022","journal-title":"Hemasphere"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000848988.44172.ff","article-title":"P1533 Trial in progress: a randomized, double-blind, placebo-controlled phase 3 study of the efficacy and safety of parsaclisib in patients with primary warm autoimmune hemolytic anemia","volume":"6","author":"Barcellini","year":"2022","journal-title":"Hemasphere"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome Short title","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.05.009","article-title":"Ibrutinib treatment for 2 cases of relapsed\/refractory autoimmune hemolytic anemia: a pilot study","volume":"41","author":"Fang","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"New Engl J Med"},{"key":"B80","volume-title":"The safety and efficacy of ibrutinib in refractory\/relapsed autoimmune hemolytic anemia","year":"2020"},{"key":"B81","unstructured":"HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169652","article-title":"Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD) of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia","volume":"140","author":"Kuter","year":"2022","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153437","article-title":"Bortezomib for the management of relapsed or refractory warm autoimmune hemolytic anemia: A scoping review","volume":"138","author":"Johnson","year":"2021","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-821868","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"B85","volume-title":"The safety of repurposing daratumumab for relapsed or refractory autoimmune antibody mediated hemolytic anemia (DARA-AIHA)","year":"2020"},{"key":"B86","volume-title":"Safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia (wAIHA)","year":"2020"},{"key":"B87","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1212\/WNL.96.15_supplement.2157","article-title":"Vivacity-MG: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis","volume":"96","author":"Guptill","year":"2021","journal-title":"Neurology"},{"key":"B88","volume-title":"Efficacy and safety of M281 in adults with warm autoimmune hemolytic anemia","year":"2019"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1228142\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:29:25Z","timestamp":1703208565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1228142\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2023.1228142"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1228142","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"article-number":"1228142"}}